Neurology

Nicole Boczek, Ph.D., and Sarah Barnett, M.S., CGC, explain how Mayo Clinic Laboratories' whole genome sequencing provides comprehensive information for rapid diagnosis of hereditary disorders.

By Barbara J. Toman • February 28, 2023

In this month's "Hot Topic," Eoin Flanagan, M.B., B. Ch., discusses the important issue of autoimmune encephalitis misdiagnosis and identifies red flags that be useful in clinical practice to suggest alternative diagnoses and highlight antibodies that sometimes cause confusion.

By MCL Education • February 20, 2023

Mayo Clinic Laboratories expanded movement disorders panel better identifies autoimmune conditions. Four recently identified biomarkers — septin-5, septin-7, neurochondrin, and adaptor protein-3B2 — have been added to the panel, and all four have been shown to respond to immunotherapy.

By Cory Pedersen • February 8, 2023

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.

By Barbara J. Toman • February 7, 2023

PACE
In this month’s “Virtual Lecture” Eoin Flanagan, M.D., B.Ch., reviews how to diagnose autoimmune encephalitis, what to watch that may suggest a different diagnosis, discuss neural autoantibodies interpretation and putting test results into clinical context.

By MCL Education • January 18, 2023

Education on this topic decreases misdiagnosis and the possibility of misinterpreting the comments provided by the reporting laboratories.

By Barbara J. Toman • January 17, 2023

As part of Mayo Clinic’s Neuro-Oncology practice, the Division of Laboratory Genetics and Genomics tests about 50 brain tumors a week, and upwards of 1,500 brain tumors a year from all over the world.

By Chris Bahnsen • January 2, 2023

Ed Garber spent months in physical and neurological decline while a cohort of care providers and specialists searched for the root cause of his symptoms. That search for answers ended after testing by Mayo Clinic Laboratories gave them the confirmatory diagnosis they needed.

By Cory Pedersen • December 5, 2022

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.

By Barbara J. Toman • October 18, 2022

Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.

By Barbara J. Toman • August 23, 2022

Mayo Clinic Laboratories offers an innovative testing solution for the early detection of Alzheimer's disease. Learn more at the AAIC 2022 tradeshow.

By Meghann Southwick • July 27, 2022

Joshua Bornhorst, Ph.D., describes the new, FDA-approved Alzheimer's disease (AD) test and how it differs from Mayo Clinic Laboratories' existing AD evaluation. The laboratory will offer both tests, to ensure flexibility and options for managing clinical care.

By Barbara J. Toman • July 26, 2022

Mayo Clinic neuropathologist Caterina Giannini, M.D., Ph.D., received the American Association of Neuropathologists’ (AANP) award for Meritorious Contributions to Neuropathology during the AANP’s 98th annual meeting in June.

By Cory Pedersen • July 18, 2022